BioGaia AB/Skr BIOG B
1D1W1MYTD1Y5YMAX
Capital at risk
About BioGaia AB
BioGaia AB is a Swedish biotechnology company that specializes in the development and commercialization of probiotic products. The company's core business revolves around creating proprietary probiotic strains that are used to support digestive health. Notably, BioGaia's products are often formulated into dietary supplements, as well as being incorporated into infant formula and dairy products. Founded in 1990, BioGaia is headquartered in Stockholm, Sweden, and operates on a global scale, distributing its products in over 100 countries. The company is strategically positioned through its research collaborations and partnerships, enhancing its competitive strengths in the probiotic segment.
- Ticker
- Skr BIOG B
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 251
- Headquarters
- Stockholm, Sweden
- Website
- www.biogaiagroup.com
BioGaia AB Metrics
BasicAdvanced
kr 11B
31.40
kr 3.43
0.32
kr 4.00
1.52%
Price and volume
Market cap
kr 11B
Beta
0.32
52-week high
kr 136.30
52-week low
kr 96.20
Average daily volume
157K
Dividend rate
kr 4.00
Financial strength
Current ratio
4.443
Quick ratio
2.108
Interest coverage (TTM)
89.11%
Profitability
EBITDA (TTM)
454.583
Gross margin (TTM)
73.01%
Net profit margin (TTM)
21.97%
Operating margin (TTM)
27.70%
Effective tax rate (TTM)
21.87%
Revenue per employee (TTM)
kr 6,300,000
Management effectiveness
Return on assets (TTM)
19.77%
Return on equity (TTM)
30.78%
Valuation
Price to earnings (TTM)
31.405
Price to revenue (TTM)
6.893
Price to book
9.86
Price to tangible book (TTM)
11.48
Price to free cash flow (TTM)
36.358
Free cash flow yield (TTM)
2.75%
Free cash flow per share (TTM)
2.962
Dividend yield (TTM)
3.71%
Forward dividend yield
1.52%
Growth
Revenue change (TTM)
9.78%
Earnings per share change (TTM)
21.30%
3-year revenue growth (CAGR)
9.22%
10-year revenue growth (CAGR)
12.65%
3-year earnings per share growth (CAGR)
-5.89%
10-year earnings per share growth (CAGR)
4.69%
3-year dividend per share growth (CAGR)
4.19%
10-year dividend per share growth (CAGR)
10.47%
Bulls say / Bears say
Q2 2026 net sales reached SEK 440.9 million and EBIT expanded to SEK 132.1 million with a 30% margin, evidencing robust segment execution and operating leverage (Reuters)
Q2 2026 adjusted EPS of SEK 1.02 reflects improved earnings quality and effective cost management year-on-year (Reuters)
Peer-reviewed study in Food and Bioprocess Technology confirmed BioGaia’s patented LongevityGuard technology significantly extends probiotic shelf life, reinforcing its IP moat and product differentiation (Reuters)
APAC sales declined by 6% excluding currency effects in Q2 2026, driven by order variability in China and South Korea, underscoring geographic execution risks (Marketscreener)
Q1 2026 EBIT margin remained static at 27% despite 15% organic sales growth, indicating limited downside cost efficiencies under current operating model (Reuters)
Growth including currency effects was only 9% in Q2 2026, highlighting potential volatile impacts from FX fluctuations on reported financials (BioGaia)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Upcoming events
No upcoming events
Funds containing BioGaia AB
AllEURGBPUSD
Fund name | Fund size | Skr BIOG B weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.06% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.06% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.